BeiGene
BGNE
#881
Rank
ยฃ16.89 B
Marketcap
ยฃ153.91
Share price
1.71%
Change (1 day)
-1.81%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total liabilities

Total liabilities on the balance sheet as of June 2024 : ยฃ1.78 B

According to BeiGene 's latest financial reports the company's total liabilities are ยฃ1.78 B. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

BeiGene - Total liabilities on balance sheet (from 2014 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31ยฃ1.78 B7.9%
2022-12-31ยฃ1.64 B-7.08%
2021-12-31ยฃ1.77 B39.99%
2020-12-31ยฃ1.26 B165.51%
2019-12-31ยฃ0.47 B22.88%
2018-12-31ยฃ0.38 B45.04%
2017-12-31ยฃ0.26 B525.12%
2016-12-31ยฃ42.87 M49.86%
2015-12-31ยฃ28.61 M59.92%
2014-12-31ยฃ17.89 M-41.52%
2013-12-31ยฃ30.59 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
ยฃ9.26 M-99.48%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ0.44 B-75.08%๐Ÿ‡บ๐Ÿ‡ธ USA